Abbott establishes new research laboratory in Singapore

This new facility, Abbott’s first pharmaceutical R&D site in Southeast Asia, will conduct stability studies, including studies on active pharmaceutical ingredients and novel formulations, to support global regulatory requirements for new pharmaceutical products.

The work done at the laboratory will enable Abbott to accelerate the development of innovative investigational medicines and potentially deliver new treatments to patients faster in areas such as neuroscience and cancer.

John Leonard, senior vice president of pharmaceuticals and R&D at Abbott, said: “Abbott has continually increased its investment in R&D over the last decade, resulting in a promising pipeline. To realize the potential from the growth in Abbott’s early stage pipeline requires the resources of a truly global R&D organization and the scientific talent available in Singapore made it a logical choice for Abbott’s expansion in the region.”